Drug Profile
Tivantinib companion diagnostic - Merck & Co/Daiichi Sankyo
Alternative Names: MET companion diagnostic - ArQule/Daiichi SankyoLatest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule; Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Merck & Co
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in liver cancer(Diagnosis) in European Union
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in liver cancer(Diagnosis) in USA